Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Publication year range
1.
Tumour Biol ; 36(3): 1519-27, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25374062

ABSTRACT

Serum marker evaluation is an easily available prognostic indicator that may help clinicians to discriminate patients with an aggressive disease; there are few and small-sized studies exploring the prognostic role of baseline carcinoembryonic antigen (CEA) values and their variations during first-line therapy, and even fewer data are available for carbohydrate antigen 19-9 (CA 19-9). Our aim was to analyze the role of those prognostic markers to exploit them in daily clinical practice. Data of 892 patients with marker determination before and 3 and/or 6 months during therapy were extracted from two institutional databases. Patients were grouped according to single marker variation as always negative (G0), decreasing (G1), stable (G2), or increasing (G3). We evaluated the progression-free survival (PFS) and the overall survival (OS) of all the patents and correlated them with CEA and CA 19-9 values. A concordance between response to therapy and marker decrease was evident in 50.2% and in 34.4% of the patients for CEA and CA 19-9. Patients with low CEA or CA 19-9 baseline values had a longer PFS (15.1 vs. 10.5; 13.6 vs. 10.2 months) and OS (32.0 vs. 22.3; 30.5 vs. 20.1 months). The same results of PFS and OS were obtained by analyzing the data of the four different groups. Multivariate analyses confirmed the independent prognostic role of CEA and CA 19-9. Baseline CEA and CA 19-9 levels and their kinetics demonstrated to be independent prognostic factors. CA 19-9 dosage is not recommended; a possible role of CA 19-9 in patients with negative CEA could be worth further evaluation.


Subject(s)
CA-19-9 Antigen/metabolism , Carcinoembryonic Antigen/metabolism , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/metabolism , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Biomarkers, Tumor/metabolism , Colorectal Neoplasms/drug therapy , Disease-Free Survival , Female , Humans , Male , Middle Aged , Prognosis
2.
Cancer ; 73(2): 253-8, 1994 Jan 15.
Article in English | MEDLINE | ID: mdl-8293385

ABSTRACT

BACKGROUND: The authors have previously demonstrated in different experimental models that sustained processes of cellular growth are characterized by alterations of cholesterol metabolism not only in the proliferating tissues but also in the plasma compartment. METHODS: To evaluate whether alterations of cholesterol metabolism similar to those observed in experimental models are also associated with human cancer, in the present study cholesterol distribution in tumor tissues and lipid composition in the plasma compartment were determined in patients with different types of gastrointestinal cancer. RESULTS: The results showed that tumor tissues contain increased amounts of cholesterol when compared with the corresponding normal tissues. Intracellular alterations of cholesterol were accompanied by specific changes of cholesterol in the plasma compartment: high-density lipoprotein (HDL) cholesterol was markedly reduced in the serum of patients with gastrointestinal cancer and the lipoprotein profiles showed a decrease in HDL3 fraction, the main HDL subfraction in human serum. The decrease of HDL cholesterol was negatively associated with the clinical stage of the disease. No changes in either total or low-density lipoprotein cholesterol levels were observed. CONCLUSIONS: A major function attributed to HDL is to maintain normal cell cholesterol homeostasis by removing excess of cholesterol from intracellular pools. Because the use and storage of cholesterol are increased within the tumor tissues during growth, it is possible to hypothesize that low HDL levels observed in patients with gastrointestinal cancer are associated with the increased cholesterol metabolism in proliferating tissues.


Subject(s)
Cholesterol, HDL/blood , Cholesterol/metabolism , Gastrointestinal Neoplasms/metabolism , Adult , Aged , Cholesterol/blood , Cholesterol, LDL/blood , Gastrointestinal Neoplasms/blood , Gastrointestinal Neoplasms/pathology , Homeostasis , Humans , Middle Aged , Neoplasm Staging , Tissue Distribution
3.
Oncol Rep ; 1(4): 779-82, 1994 Jul.
Article in English | MEDLINE | ID: mdl-21607440

ABSTRACT

Carcinoembryonic antigen and CA 19.9 are markers of colorectal neoplasms, often related to tumor burden. Elevated pre-operative levels parallel disease extent and may foresee adverse prognosis. CEA and CA 19.9 may increase post-operatively, indicating tumor recurrence. Only limited data are available on the influence of chemotherapeutic treatments on these two markers, to detect chemotherapy-induced cytolysis. We measured CEA and CA 19.9 before and after a chemotherapy regimen of five days consisting of folinic acid and 5-fluorouracil in forty patients with colorectal cancer. No consistent fluctuation was detected, the examined tumor markers being related in a given patient only to tumor burden.

4.
Article in English | MEDLINE | ID: mdl-1723534

ABSTRACT

We have evaluated tumor-associated trypsin inhibitor (TATI) as a marker for pancreatic and hepatic cancer. Of the patients studied 52 had pancreatic cancer, 30 primary liver cancer, 32 chronic pancreatitis, 25 biliary tract inflammatory disease, and 28 liver cirrhosis. A considerable number of falsely elevated values were observed in benign biliary diseases and in chronic relapsing pancreatitis. In pancreatic cancer the sensitivity of TATI was 63% while that of CEA was 40% and of CA19-9 77%. TATI is a marker of pancreatic disease but it does not differentiate between pancreatitis and pancreatic cancer. In liver cancer TATI and AFP has similar sensitivity and specificity.


Subject(s)
Biomarkers, Tumor/blood , Liver Neoplasms/diagnosis , Pancreatic Diseases/diagnosis , Pancreatic Neoplasms/diagnosis , Trypsin Inhibitor, Kazal Pancreatic/blood , Antigens, Tumor-Associated, Carbohydrate/blood , Carcinoembryonic Antigen/blood , Humans , Liver Neoplasms/blood , Pancreatic Diseases/blood , Pancreatic Neoplasms/blood , Predictive Value of Tests , alpha-Fetoproteins/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...